Senticore

Senti Biosciences is a clinical-stage biotechnology company pioneering the development of next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company's technology enables the engineering of "smart" therapies that can sense and respond to disease environments, potentially improving therapeutic precision, efficacy, and safety. Senti Bio's lead programs, including SENTI-202 and SENTI-301A, utilize logic-gated Chimeric Antigen Receptor (CAR) Natural Killer (NK) cells to target hematologic malignancies and solid tumors. By integrating sophisticated biological computing into various therapeutic modalities, the company aims to address complex diseases that have remained resistant to conventional treatments.